Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ICAM1 near-infrared photoimmunotherapy conjugate
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-ICAM1 near-infrared photoimmunotherapy conjugate is an experimental therapeutic agent designed for the treatment of radioresistant esophageal squamous cell carcinoma. It consists of a monoclonal antibody targeting Intercellular Adhesion Molecule 1 (ICAM1) conjugated to a near-infrared (NIR) photosensitizer. The mechanism of action involves the selective binding of the conjugate to ICAM1-expressing tumor cells, followed by activation with NIR light. This activation induces rapid cell membrane damage and immunogenic cell death. The agent is currently being studied by Zhejiang Cancer Hospital in ex vivo models using tumor fragments from patients with recurrent disease to evaluate its potential to overcome radiotherapy resistance and stimulate lymphocyte infiltration.
- Other names
- ICAM1-targeted near-infrared photoimmunotherapy conjugateICAM-1-targeted near-infrared photoimmunotherapy conjugateICAM 1-targeted near-infrared photoimmunotherapy conjugateanti-ICAM1 NIR-PITanti-ICAM-1 NIR-PITanti-ICAM 1 NIR-PIT
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on anti-ICAM1 near-infrared photoimmunotherapy conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ICAM1 near-infrared photoimmunotherapy conjugate.